HomeAXGN • NASDAQ
AxoGen, Inc Common Stock
$6.32
Apr 19, 2:38:56 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed securityUS headquartered
Previous close
$6.55
Day range
$6.31 - $6.60
Year range
$3.45 - $10.83
Market cap
273.06M USD
Avg Volume
323.82K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
42.92M18.69%
Operating expense
36.96M3.72%
Net income
-3.89M28.11%
Net profit margin
-9.0739.41%
Earnings per share
-0.06-100.00%
EBITDA
-1.58M67.79%
Effective tax rate
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
31.02M-36.41%
Total assets
196.83M0.74%
Total liabilities
101.16M7.18%
Total equity
95.66M
Shares outstanding
43.21M
Price to book
2.95
Return on assets
-4.08%
Return on capital
-4.74%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
-3.89M28.11%
Cash from operations
-211.00K-115.49%
Cash from investing
-277.00K77.09%
Cash from financing
418.00K-48.59%
Net change in cash
-70.00K-107.25%
Free cash flow
-316.12K92.55%
About
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator. As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Founded
2002
Employees
427
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu